1,735,637 research outputs found
Advancement of the gene and nucleic acid medicines from a standpoint of healthcare needs
No full textThe gene and nucleic acid medicines have attracted attention as novel drugs by advance of molecular biology and genetics. The gene and nucleic acid medicines are used to age-related macular degeneration
and spinal muscular atrophy in clinical practice. However, it is not enough for gene and nucleic acid medicines to integrate the information on quality and safety. Their target diseases and administration routes are limited by low bioavailability because of low stability and poor membrane permeability. Clinical development of gene and nucleic acid medicines need to integrate non-clinical and clinical information and create adequate regulation.It is also necessary to develop chemical modification and DDS for the gene and nucleic acid medicines to increase the stability and organ delivery. Many studies have not produced practical DDS for gene and nucleic acid medicines. Safety and biocompatibility of DDS are very important for clinical use.
Most DDS has been developed by the seeds, not healthcare needs. So, we have developed the multi-functional and effective DDSs (Nano-ball） constructed with safe materials of medicines and foods. The spleen targeting Nano-ball have been developed to show its high efficiency as cancer vaccine and infectious vaccine after extensive screenings. siRNA Nano-ball showed therapeutic effect against metastasis of melanoma and peritoneal dissemination of colon cancer in mice. The lung targeting Nano-ball showed a relationship between Nano-ball contents and organ distribution.
Nano-ball was able to be prepared by sterilized mass production. Early clinical use of Nano-ball is expected because of their efficacy and safety. We would like to discuss advancement of the gene and nucleic acid medicines from a standpoint of healthcare needs.遺伝子・核酸医薬は安定性や膜透過性が低く、精密な標的化が難しいため、対象疾患や投与法が限定されている。
さらなる臨床展開のためには、非臨床・臨床情報を集積し、規制を整備することが重要である。また、生体内安定性や細胞標的性、臓器選択性を付与できる化学修飾やDDSの開発が強く望まれる。国内外で、数多くのDDSが研究されてきたが、未だ実用化は難しく、臨床使用を目的とした安全性や生体適合性を考慮する必要がある。さらにシーズ開発が優先され、臨床ニーズとのマッチングが不十分である。筆者らは、医薬品や食品などに使用されている安全な素材を用いて、遺伝子・核酸医薬に適したDDSを構築した。薬理効果や毒性を検討し、その結果を製剤設計へのフィードバックを繰り返すことで、多機能で安全なDDS（ナノボール）を開発した。ナノボールは無菌的な大量生産も可能で汎用性が高い。高い安全性から臨床への早い応用も期待できる。臨床現場や臨床ニーズの立場から、遺伝子・核酸医薬の開発の課題や展望について考える
DDS技術を活用した獣医再生治療
No full textapplication/pdfRecently, regenerative medicine with autologous cells and tissues has been carried out for tissue regeneration. Basic research and clinical application based on tissue engineering have also been reported in joint cartilage regeneration. The physiological connection between the cartilages newly regenerated and natural ones is not always sufficient. Currently, to tackle the problem, the clinical application of DDS-based cartilage regeneration therapy has been tried. This paper introduces the research results of bone regeneration and articular cartilage regeneration in the veterinary medical field. c 2017, Japan Society of Drug Delivery System. All rights reserved.journal articl
A DDS-based approach to a FM exciter: design and FPGA implementation
No full textembargoed_20271127La Sintesi Digitale Diretta (DDS) rappresenta un approccio efficiente e ad alte prestazioni per l’implementazione degli schemi di modulazione più semplici. Tale caratteristica la rende una scelta eccellente per la realizzazione di un eccitatore FM, offrendo un’alternativa moderna alle tradizionali tecniche di modulazione analogica e ai loro caratteristici limiti. Questo lavoro presenta nel dettaglio l’implementazione e l’analisi di un eccitatore FM basato sul circuito integrato DDS AD9910 di Analog Devices, affiancato da un FPGA per la gestione del sistema e l’elaborazione digitale del segnale. Lo studio abbraccia tutte le fasi progettuali fondamentali: dall’analisi teorica delle non-idealità nella modulazione digitale, allo sviluppo di un prototipo personalizzato, per concludere con misure dettagliate che dimostrano le prestazioni e la funzionalità del sistema.Direct Digital Synthesis (DDS) offers an efficient and high-performance approach to implementing basic modulation schemes. This makes it an excellent candidate for realizing an FM exciter, providing a modern alternative to traditional analog modulation techniques and their inherent limitations. This work presents the complete development and analysis of a practical FM exciter implementation based on the Analog Devices AD9910 DDS integrated circuit, complemented by an FPGA for control and digital signal processing. The work encompasses all crucial design stages, beginning with a theoretical examination of digital modulation non-idealities, proceeding through the development of a custom prototype, and concluding with comprehensive measurements that demonstrate the system’s performance and functionality
mehdi-karimi-math/DDS: DDS 2.1
No full textThis is the version of DDS reviewed and accepted for publication in the Journal of Mathematical Programming Computation
臨床応用に有用な基礎研究の進歩
No full textWhile the development of a new medicine makes little increase, improvement in the efficacy and safety of the existing drug can be achieved by new DDS formation in clinical each subject (respiratory organ, circulatory organ, otolaryngology and infectious disease). The introduction of biomaterial and control of targeting functions is the key to improve the disposition characteristics of a drug in DDS development. On the other hand, revision of the Japanese Pharmacopoeia was performed according to new dosage forms.In this paper, the present condition of the DDS formulation for clinical application was reviewed in clinical each subject and infectious disease. Furthermore, I outlined the basic DDS research supporting the development of new DDS formulation. In particular, I focused on inhalation device, stent, new injection devise and vaccine.新薬開発が伸び悩む近年、臨床各科（呼吸器、循環器、耳鼻科）および感染症領域では、DDS製剤化による既存薬の有効性および安全性の向上が図られている。臨床各科でのDDS製剤の開発においては、薬物の放出制御や標的指向化など、目的とする機能を有する生体材料の導入と高度な製剤技術が成功の鍵を握っている。このような背景により、新規剤形の追加などの日本薬局方の改正も実施された。本稿では、臨床各科および感染症領域において、実際に臨床応用されているDDS製剤の現況をまず整理して、既存薬のDDS製剤化に関して臨床応用に有用な基礎研究の進歩を概説する。特に、吸入デバイス（呼吸器）、ステント（循環器）、新規投与デバイス（耳鼻科）およびワクチン（感染症）に絞って紹介する。Drug Delivery System, 27(2), pp.106-115; 2012journal articl
A synchronised Direct Digital Synthesiser
No full textWe describe a Direct Digital Synthesiser (DDS) which provides three frequency-locked synchronised outputs to generate frequencies from DC to 160 MHz. Primarily designed for use in a heterodyning range imaging system, the flexibility of the design allows its use in a number of other applications which require any number of stable, synchronised high frequency outputs. Frequency tuning of 32 bit length provides 0.1 Hz resolution when operating at the maximum clock rate of 400 MSPS, while 14 bit phase tuning provides 0.4 mrad resolution. The DDS technique provides very high relative accuracy between outputs, while the onboard oscillator’s stability of ±1 ppm adds absolute accuracy to the design
Ampliamento del centro sportivo DDS, Settimo Milanese, Milano
No full textpubblicazione del progetto costruito di una piscina coperta e di una palestra nell'area metropolitana milanese del centro sportivo privato DDS Dimensione Dello Sport a Settimo Milanese (MI
FairRootGroup/DDS: 3.8
No full text<p><details>
<summary>Release Notes</summary>
## v3.8 (2024-01-19)</p>
<ul>
<li><p>DDS general</p>
<ul>
<li>Fixed: On task done remove agents from the agent to tasks mapping.</li>
<li>Fixed: Replace std::iterator as it's deprecated (C++17).</li>
<li>Fixed: Tasks working directory is set to their slot directory instead of DDS_LOCATION.</li>
<li>Fixed: Multiple stability issues.</li>
<li>Modified: support C++20 standard (GH-477).</li>
<li>Modified: Bump minimum version requirements for cmake (from 3.11.0 to 3.19) and boost (from 1.67 to 1.75). (GH-428)</li>
<li>Modified: C++17 modernization of EnvProp.h/env_prop. (GH-368)</li>
<li>Added: 3rd party dependency on Protobuf (min v3.15).</li>
<li>Added: every DDS module logs now its pid, group id and parent pid. (GH-403)</li>
<li>Added: Support for Task Assets. (GH-406)</li>
<li>Added: Cancel running and pending SLURM jobs on DDS shutdown. (GH-429)</li>
<li>Added: Support for Apple's arm64 architecture. (GH-393)</li>
<li>Added: DDS_CONFIG and <code>/etc/dds/DDS.cfg</code> are added to the DDS config search paths. (GH-458)</li>
<li>Added: DDS libraries are now decorated with an ABI version. (GH-410)</li>
</ul>
</li>
<li><p>dds-agent</p>
<ul>
<li>Fixed: Address potential crash in the external process termination routines.</li>
<li>Fixed: Revised handling of the slots container.</li>
<li>Fixed: Ignore SIGTERM while performing cleaning procedures. (GH-459)</li>
</ul>
</li>
<li><p>dds_intercom_lib</p>
<ul>
<li>Fixed: Stability improvements.</li>
<li>Modified: Temporary increase intercom message size to 2048. (GH-440)</li>
<li>Modified: Set debug log severity on Custom command events. (GH-424)</li>
</ul>
</li>
<li><p>dds-session</p>
<ul>
<li>Fixed: skip bad or non-session directories/files when performing clean and list operations.</li>
<li>Added: A data retention sanitization. Not running sessions older than the specified number of days ("server.data_retention") are auto deleted. (GH-435)</li>
</ul>
</li>
<li><p>dds-submit</p>
<ul>
<li>Added: Users can specify a GroupName tag for each submission. This tag will be assigned to agents and can be used as a requirement in topologies. (GH-407)</li>
<li>Added: Users can provide a Submission Tag (<code>--submission-tag</code>). DDS RMS plug-ins will use this tag to name RMS jobs and directories. (GH-426)</li>
<li>Added: The command learned a new argument <code>--env-config/-e</code>. It can be used to define a custom environment script for each agent. (GH-430)</li>
<li>Added: The command learned a new argument <code>--min-instances</code>. It can be used to provide the minimum number of agents to spawn. (GH-434)</li>
<li>Added: The command learned a new argument <code>--enable-overbooking</code>. The flag instructs DDS RMS plug-ing to not specify any CPU requirement for RMS jobs. (GH-442)</li>
<li>Added: The command learned a new argument <code>--inline-config</code>. Content of this string will be added to the RMS job configuration file as is. It can be specified multiple times to add multiline options. (GH-449)</li>
<li>Modified: WN package builder timeout interval was increased from 15 to 30 sec. (GH-468)</li>
<li>Modified: Improve validation of the WN package builder. (GH-468)</li>
</ul>
</li>
<li><p>dds-topology</p>
<ul>
<li>Fixed: Stability improvements.</li>
<li>Fixed: A bug which caused <code>dds::topology_api::CTopoCreator</code> to ignore task assets. (GH-452)</li>
<li>Fixed: Activating topology takes too long when task assets are used. (GH-454)</li>
<li>Fixed: a bug, which can cause a segfault when updating variables in topology.</li>
<li>Added: A new groupName requirement. It can be used on task and collection. (GH-407)</li>
<li>Added: Open API to read/update/add topology variable. The <code>CTopoVars</code> class.</li>
<li>Added: Support for Task Assets. (GH-406)</li>
<li>Added: Custom type of Task and Collection requirements. (GH-445)</li>
</ul>
</li>
<li><p>dds-ssh-plugin</p>
<ul>
<li>Fixed: ssh cfg parser is passing cfg files of all plug-ins. (GH-413)</li>
<li>Added: Support for SubmissionID (GH-411)</li>
</ul>
</li>
<li><p>dds-slurm-plugin</p>
<ul>
<li>Fixed: Make sure that scancel's SIGTERM is properly handled by all job steps and their scripts. (GH-459)</li>
<li>Added: Support for SubmissionID (GH-411)</li>
<li>Added: Support of minimum number of agents to spawn. (GH-434)</li>
<li>Modified: Replace array job submission with nodes requirement. (GH-430)</li>
<li>Modified: Remove <code>#SBATCH --ntasks-per-node=1</code>. (GH-444)</li>
<li>Modified: The <code>#SBATCH --cpus-per-task=%DDS_NSLOTS%</code> requirement is now can be disabled by providing the "enable-overbooking" flag (ToolsAPI or dds-submit). (GH-442)</li>
<li>Modified: Prevent job termination when downing a single node of the job allocation. (GH-450)</li>
</ul>
</li>
<li><p>dds-localhost-plugin</p>
<ul>
<li>Added: Support for SubmissionID (GH-411)</li>
</ul>
</li>
<li><p>dds-tools-api</p>
<ul>
<li>Modified: Logs of user processes which use Tools API are moved now to the DDS root log directory, instead of sessions directory.</li>
<li>Modified: <code>CSession::waitForNumAgents</code> is renamed to <code>CSession::waitForNumSlots</code>. (GH-439)</li>
<li>Added: An ability to unsubscribe from either individual events or all events of requests. (GH-382)</li>
<li>Added: SAgentInfoResponseData provides the agent group name. (GH-415)</li>
<li>Added: SSubmitRequestData supports flags. See <code>SSubmitRequestData::setFlag</code> and <code>SSubmitRequestData::ESubmitRequestFlags</code>. (GH-442)</li>
<li>Added: Users can define additional job RMS configuration via <code>SSubmitRequestData::m_inlineConfig</code>. It will be inlined as is into the final job script. (GH-449)</li>
</ul>
</li>
<li><p>dds-user-defaults</p>
<ul>
<li>Fixed: a dangling reference to a temporary in User Defaults class.</li>
<li>Modified: Bump the version to 0.5.</li>
<li>Added: A <code>server.data_retention</code> configuration key. (GH-435)</li>
</ul>
</li>
<li><p>dds-info</p>
<ul>
<li>Fixed: wrong exit code when called with <code>--help/--version</code>. (GH-470)</li>
</ul>
</li>
<li><p>dds-agent-cmd</p>
<ul>
<li>Modified: getlog: now logs are tar'ed without their source directory structure - as a flat stack of files. (GH-369)</li>
<li>Modified: getlog: the command outputs the destination directory where downloaded archives will be stored into. Also fixed command's description. (GH-369)<p></details></p>
</li>
</ul>
</li>
</ul>
Reduced nephrotoxicity of cisplatin in multiplephase emulsion
No full textCisplatin is an anticancer drug with broad-spec-trum, that is especially effective against genitourinary tumors. But it shows serious toxicity in kidney and gastrointestinal tract in clinical use. In order to decrease nephrotoxicity of cisplatin, several approaches have been done, such as : (1) Change of administration route and combination therapy with other drugs ; (2) Development of new derivatives : (3) Novel dosage form (design of DDS forms) ; etc. In this paper, preparation of multiple-phase emulsion containing cisplatin and its combination therapy in mouse will be presented. The physicochemical properties and nephrotoxicity of the emulsion were also investigated
MS 069 Guide to the Harold S. Skjonsby, DDS Papers (1967-1987)
No full textThe Harold S. Skjonsby, DDS, papers (MS069) contains reports, committee notes, curriculum and modules for teaching, grant information, faculty workshop programs, and student handbooks that document Harold S. Skjonsby’s time as faculty the University of Texas Dental Branch at Houston. See more at MS 069
- …
